What the name refers to
A synthetic peptide medicine used regionally, particularly in Russia, without FDA or EMA authorisation.
Evidence and regulatory context
Medical use or authorisation exists historically or in limited jurisdictions. Current availability, indications and legal classification must be checked against the regulator for the reader’s location.
Reading product records
These names do not form one pharmacological class. Each record must be read compound by compound, with special attention to the difference between an authorised medicine, an investigational candidate, a regional product and an online research listing.
Primary research links
Use current regulator and study records rather than treating a catalogue description as medical evidence.